Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Galapagos NV ADR (GLPG)

Galapagos NV ADR (GLPG)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,816,121
  • Shares Outstanding, K 65,897
  • Annual Sales, $ 259,450 K
  • Annual Income, $ 229,120 K
  • EBIT $ -12 M
  • EBITDA $ 35 M
  • 60-Month Beta 0.22
  • Price/Sales 6.94
  • Price/Cash Flow 41.96
  • Price/Book 0.57

Options Overview Details

View History
  • Implied Volatility 38.84% ( +13.66%)
  • Historical Volatility 35.61%
  • IV Percentile 41%
  • IV Rank 34.76%
  • IV High 80.76% on 07/18/24
  • IV Low 16.51% on 09/18/24
  • Put/Call Vol Ratio 5.56
  • Today's Volume 236
  • Volume Avg (30-Day) 385
  • Put/Call OI Ratio 0.07
  • Today's Open Interest 11,518
  • Open Int (30-Day) 8,609

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 10 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/24
See More
  • Average Estimate -0.03
  • Number of Estimates 3
  • High Estimate 0.11
  • Low Estimate -0.22
  • Prior Year 0.42
  • Growth Rate Est. (year over year) -107.14%

Price Performance

See More
Period Period Low Period High Performance
1-Month
26.35 +6.49%
on 10/31/24
31.23 -10.14%
on 10/21/24
-1.21 (-4.13%)
since 10/14/24
3-Month
24.25 +15.71%
on 08/15/24
31.23 -10.14%
on 10/21/24
+3.86 (+15.95%)
since 08/14/24
52-Week
24.16 +16.14%
on 08/14/24
42.46 -33.91%
on 01/08/24
-9.30 (-24.89%)
since 11/14/23

Most Recent Stories

More News
+ND Capital's European Investment Strategy Delivers Again as Sale of CellPoint to Galapagos Paves the Way for Disruptive Point-of-Care Cell Therapy Model for Cancer Patients

/PRNewswire/ -- The Lausanne-based team of US investment firm, +ND Capital, today marked its second successful exit in the European biotechnology market as...

GLPG : 28.02 (+1.67%)
Why Galapagos Trounced the Market Today

A high-profile healthcare industry executive has been tapped as the company's new CEO.

GLPG : 28.02 (+1.67%)
Galapagos and Gilead Discontinue ISABELA Phase 3 Trials in IPF

Galapagos NV (Euronext & Nasdaq: GLPG) and Gilead Sciences (Nasdaq: GILD) today announced the decision to halt the ISABELA Phase 3 clinical studies with the investigational autotaxin inhibitor ziritaxestat...

GLPG : 28.02 (+1.67%)
GILD : 92.33 (-0.32%)
Gilead and Galapagos Announce New Commercialization and Development Agreement for Jyseleca® (Filgotinib)

Gilead Sciences, Inc. (Nasdaq: GILD) and Galapagos NV (Euronext & Nasdaq: GLPG) today announced that the companies have agreed to amend their existing arrangement for the commercialization and development...

GLPG : 28.02 (+1.67%)
GILD : 92.33 (-0.32%)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Galapagos NV - GLPG

NEW YORK, Dec. 12, 2020 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Galapagos NV (“Galapagos” or the “Company”) (NASDAQ: GLPG).   Such investors are...

GLPG : 28.02 (+1.67%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Sell with a Weakest short term outlook on maintaining the current direction.

See More Share

Business Summary

Galapagos NV is a biotechnology company. The Company's operating segment consists of Research and Development and Services. Research and Development segment is engaged in the discovery and development of small molecules. Services segment offers drug discovery products and services. Its products include...

See More

Key Turning Points

3rd Resistance Point 28.29
2nd Resistance Point 28.00
1st Resistance Point 27.78
Last Price 28.02
1st Support Level 27.28
2nd Support Level 26.99
3rd Support Level 26.77

See More

52-Week High 42.46
Fibonacci 61.8% 35.47
Fibonacci 50% 33.31
Fibonacci 38.2% 31.15
Last Price 28.02
52-Week Low 24.16

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar